Literature DB >> 12888077

Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema.

Jost B Jonas1, Ingrid Kreissig, Robert F Degenring.   

Abstract

PURPOSE: To report the clinical outcome of patients undergoing intravitreal injection of triamcinolone acetonide as treatment of long-standing cystoid macular edema after phacoemulsification.
DESIGN: Prospective clinical interventional cases series studies.
METHODS: The study included five patients suffering from cystoid macular edema after cataract surgery. They received an intravitreal injection of 25-mg crystalline triamcinolone acetonide transconjunctivally with topical anesthesia.
RESULTS: In the follow-up period of 6.6 +/- 4.1 months, visual acuity increased from 0.26 +/- 0.13 to a mean maximal visual acuity of 0.60 +/- 0.19. For all patients, visual acuity improved during the follow-up by at least 0.20. Two (40%) patients developed intraocular pressure values higher than 21 mm Hg, which could be controlled by topical antiglaucomatous treatment.
CONCLUSIONS: Intravitreal triamcinolone acetonide may be a therapeutic option for long-standing cystoid macular edema after cataract surgery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12888077     DOI: 10.1016/s0002-9394(03)00230-7

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  30 in total

1.  Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study.

Authors:  A P Ciardella; J Klancnik; W Schiff; G Barile; K Langton; S Chang
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

2.  Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; R F Degenring
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

3.  Viral retinitis after intravitreal triamcinolone injection in patients with predisposing medical comorbidities.

Authors:  Ankur M Shah; Stephen F Oster; William R Freeman
Journal:  Am J Ophthalmol       Date:  2010-03       Impact factor: 5.258

4.  Pattern electroretinogram for monitoring the efficacy of intravitreal triamcinolone injection in diabetic macular edema.

Authors:  Abdullah Ozkiris; Cem Evereklioglu; Ayse Oner; Kuddusi Erkiliç
Journal:  Doc Ophthalmol       Date:  2004-09       Impact factor: 2.379

5.  The problem of pressure elevation associated with intravitreal triamcinolone.

Authors:  M D Conway
Journal:  Br J Ophthalmol       Date:  2006-08       Impact factor: 4.638

6.  Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye.

Authors:  B R Kosobucki; W R Freeman; L Cheng
Journal:  Br J Ophthalmol       Date:  2006-03-10       Impact factor: 4.638

7.  Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.

Authors:  A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-04-17       Impact factor: 4.638

8.  Primary iris claw IOL retrofixation with intravitreal triamcinolone acetonide in cases of inadequate capsular support.

Authors:  Aditya Kelkar; Rachana Shah; Viraj Vasavda; Jai Kelkar; Shreekant Kelkar
Journal:  Int Ophthalmol       Date:  2017-02-09       Impact factor: 2.031

9.  Intravitreal triamcinolone acetonide: Pattern of secondary intraocular pressure rise and possible risk factors.

Authors:  Ziad F Bashshur; Abdallah M Terro; Christelle P El Haibi; Akaber M Halawi; Alexandre Schakal; Baha' N Noureddin
Journal:  Clin Ophthalmol       Date:  2008-06

10.  Intravitreal triamcinolone for intraocular inflammation and associated macular edema.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2009-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.